Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

NCT01338870 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Placebo
DRUG: 25 mg PF-04991532
DRUG: 75 mg PF-04991532
DRUG: 150 mg PF-04991532
DRUG: 300 mg PF-04991532
DRUG: Sitagliptin 100 mg

Sponsor

Pfizer